Europe is arming itself with two new treatments to fight the Coronavirus.
The European Medicines Agency (EMA) on Thursday approved the monoclonal antibody treatment of GlaxoSmithKline as well as an immunosuppressive drug already authorized in the EU for various inflammatory conditions.
GSK "is intended for the treatment of Covid-19 in adults and adolescents who do not need supplemental oxygen and who are at increased risk of the severity of the disease," the EMA said in a statement, while the use of the Kineret has been “extended to the treatment of Covid-19 in adult patients (…) who need supplemental oxygen (…) and who are at risk of developing severe respiratory failure”.
Health
Coronavirus: Switzerland launches a project on four anti-Covid-19 treatments with Swiss companies
EU
Europe
Covid 19
Medication
Processing
Health
Coronavirus
0 comment
0 share
Share on Messenger
Share on Facebook
Share on twitter
Share on Flipboard
Share on Pinterest
Share on Linkedin
Send by Mail
To safeguard
A fault ?
To print